|
Name |
Pullularin E
|
Molecular Formula | C42H57N5O8 | |
IUPAC Name* |
(6S,9S,12S,15S,18S)-3-benzyl-12-[(2S)-butan-2-yl]-6,7,13,15-tetramethyl-9-[[4-(3-methylbut-3-enoxy)phenyl]methyl]-4-oxa-1,7,10,13,16-pentazabicyclo[16.3.0]henicosane-2,5,8,11,14,17-hexone
|
|
SMILES |
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N([C@H](C(=O)OC(C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N1C)C)CC3=CC=CC=C3)C)C)CC4=CC=C(C=C4)OCCC(=C)C
|
|
InChI |
InChI=1S/C42H57N5O8/c1-9-27(4)36-38(49)44-33(24-31-17-19-32(20-18-31)54-23-21-26(2)3)40(51)45(7)29(6)42(53)55-35(25-30-14-11-10-12-15-30)41(52)47-22-13-16-34(47)37(48)43-28(5)39(50)46(36)8/h10-12,14-15,17-20,27-29,33-36H,2,9,13,16,21-25H2,1,3-8H3,(H,43,48)(H,44,49)/t27-,28-,29-,33-,34-,35?,36-/m0/s1
|
|
InChIKey |
SDUUWTNLMDCMFD-ZOPCHVBZSA-N
|
|
Synonyms |
Pullularin E
|
|
CAS | NA | |
PubChem CID | 139586396 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 759.9 | ALogp: | 5.9 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 155.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 55 | QED Weighted: | 0.27 |
Caco-2 Permeability: | -5.155 | MDCK Permeability: | 0.00004460 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0.019 |
Human Intestinal Absorption (HIA): | 0.055 | 20% Bioavailability (F20%): | 0.011 |
30% Bioavailability (F30%): | 0.851 |
Blood-Brain-Barrier Penetration (BBB): | 0.008 | Plasma Protein Binding (PPB): | 85.27% |
Volume Distribution (VD): | 0.531 | Fu: | 5.63% |
CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.054 |
CYP2C19-inhibitor: | 0.264 | CYP2C19-substrate: | 0.472 |
CYP2C9-inhibitor: | 0.655 | CYP2C9-substrate: | 0.143 |
CYP2D6-inhibitor: | 0.017 | CYP2D6-substrate: | 0.235 |
CYP3A4-inhibitor: | 0.965 | CYP3A4-substrate: | 0.688 |
Clearance (CL): | 7.204 | Half-life (T1/2): | 0.288 |
hERG Blockers: | 0.052 | Human Hepatotoxicity (H-HT): | 0.991 |
Drug-inuced Liver Injury (DILI): | 0.949 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.868 | Maximum Recommended Daily Dose: | 0.942 |
Skin Sensitization: | 0.036 | Carcinogencity: | 0.025 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.025 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002484 | 0.815 | D0E2OU | 0.369 | ||||
ENC002483 | 0.756 | D0J7XL | 0.342 | ||||
ENC003591 | 0.455 | D07XGH | 0.305 | ||||
ENC003645 | 0.429 | D05MNW | 0.305 | ||||
ENC004971 | 0.394 | D09PZZ | 0.298 | ||||
ENC001481 | 0.386 | D09NNH | 0.298 | ||||
ENC002515 | 0.373 | D0U7SH | 0.295 | ||||
ENC003706 | 0.369 | D01TSI | 0.292 | ||||
ENC005563 | 0.366 | D0N4OW | 0.292 | ||||
ENC002514 | 0.362 | D0D8XY | 0.291 |